U.S. Markets closed

SANUWAVE Health, Inc. (SNWV)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2150+0.0051 (+2.43%)
At close: 3:25PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2110
Open0.2100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2100 - 0.2150
52 Week Range0.1100 - 0.3200
Volume18,660
Avg. Volume246,318
Market Cap70.223M
Beta (5Y Monthly)-0.59
PE Ratio (TTM)N/A
EPS (TTM)-0.0450
Earnings DateMay 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.34
  • GlobeNewswire

    SANUWAVE® Health to Participate in Multiple U.S. Wound Care Medical Meetings in October

    Highlighting the clinical advantages of the Company’s ‘Energy First’ approach to healing chronic wounds with dermaPACE® and UltraMIST® Systems SUWANEE, GA, Sept. 30, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, announced today that the Company will be participating in a number of important medical meetings focused on innovative treatments in wound care, where it will highlight the clinical merits of its “Energy First” approach to treating advanced wounds with dermaPACE® shockwave medical system and UltraMIST® ultrasound medical system. SANUWAVE Health will participate in the following virtual meetings in October:·       DFCon20 (October 9 – 10, 2020), the world’s premier interdisciplinary Diabetic Foot Conference in North America, where SANUWAVE will sponsor a virtual symposium. The virtual symposium titled, “Energy First: UltraMIST® Pathway to Improved Wound Healing Outcomes,” will be presented by Donald Mrdjenovich, DPM, CWS, FACCWS. Dr. Mrdjenovich is a board-certified wound specialist (CWS®) in private practice with Central PA Physicians Group. The virtual symposium takes place on Saturday, October 10th from 7:30 am – 8:00 am (EST). In addition, SANUWAVE is an exhibitor and sponsor of this prestigious diabetic foot ulcer (DFU) conference, where besides UltraMIST® System, the company will also showcase dermaPACE® System along with the Company’s complementary biologic healing therapies (Biovance® and InterFyl®) for advanced wound care. ·       PRESENT e-Learning Systems (October 13, 2020) where SANUWAVE will be providing an unrestricted educational grant to support an accredited live webinar. The live webinar titled, “Energy First: Extracorporeal Shockwave Therapy (ESWT) in the Treatment of Diabetic Foot Ulcers” will be presented from 12:00 pm – 1:00 pm ET by Anthony Tickner, DPM, FACCWS, FAPWH, FAPWCA, FFPM RCPS (Glasg), Medical Director, St. Vincent Hospital/Restorix Health Wound Healing Center.·       The Academy of Physicians in Wound Healing/2020 Virtual Scientific Symposium (October 16-18, 2020) where SANUWAVE will be participating in the Scientific Symposium as an exhibitor and in supporting a Certification Sponsorship. The Certification Sponsorship program provides financial assistance to residents, physicians, nurse practitioners and physician assistants to become certified in wound healing. Throughout the symposium and at the exhibit booth, the company will highlight its entire advanced wound care product portfolio.·       The American College of Hyperbaric Medicine (ACHM) First Annual Advanced Wound Care and Hyperbaric Virtual Conference (October 24-25, 2020) where SANUWAVE will be exhibiting its suite of advanced wound care products.“Healing chronic wounds remain a challenge for wound care specialists and can lead to loss of function, decreased quality of life, and are a significant cause of morbidity for the patients who suffer with them.1 2  Using energy transfer technologies, such as UltraMIST®, has demonstrated improved healing in a variety of recalcitrant and unhealing wounds,” noted Dr. Mrdjenovich. “These upcoming October wound care conferences in the U.S. offer SANUWAVE exceptionally broad-based exposure to the country’s leading wound care specialists given the diversity of audiences in attendance at each. We continue to support and develop symposia that educate wound care specialists on the clinical merits of our ‘Energy First’ products and how they can significantly improve the outcomes for their patients with chronic, unhealing wounds,” stated Kevin A. Richardson II, Chairman and Chief Executive Officer of SANUWAVE Health.“The synergistic mechanisms of action of our UltraMIST® and dermaPACE® allow us to provide a multimodal treatment approach to wound management and healing.  These products create a significant opportunity to improve patient outcomes when compared to only current standard-of-care, initially for DFUs, with a plan for all wound indications in the future,” added Mr. Richardson.About UltraMIST® SystemUltraMIST® System is providing through a fluid mist a low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The ultrasound acoustic waves promote healing by reducing inflammation and bacteria in the wound bed, while also increasing the growth of new blood vessels to the area.  The UltraMIST® System treatment must be administered by a healthcare professional.  This proprietary technology has been cleared by the U.S. Food and Drug Administration (FDA) for the promotion of wound healing through wound cleansing and maintenance debridement combined with ultrasound energy deposited inside the wound that stimulated tissue regeneration.  The UltraMIST® System has been used in thousands of patients for more than a decade.  For international markets, the UltraMIST® System is CE Marked in Europe.About the dermaPACE® SystemThe dermaPACE® System is a novel medical system based on shockwave technology, which has been used for nearly 30 years in lithotripsy procedures (destruction of kidney stones) and later in orthopedic treatments.  These early lithotripsy and orthopedic devices provided the earliest evidence that there was an effect on wound healing. Pulsed Acoustic Cellular Expression (PACE®) Technology was developed based on this evidence, and the dermaPACE® System is the first to utilize PACE-specific proprietary protocols for wound treatment.  The dermaPACE® System treatment must be administered by a healthcare professional.  The dermaPACE® System is FDA cleared for the treatment of diabetic foot ulcers (DFU) and it is the first and only system based on focused electrohydraulic shockwave principle cleared by the FDA for such indication.   For international markets, the dermaPACE® System is CE Marked in Europe for advanced wound care indications and in Canada carries a Health Canada Medical Device class II License. The dermaPACE® System is currently licensed or approved for advanced wound care indications in dozens of countries and regions around the world. About SANUWAVE Health, Inc.SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.  Through its recent acquisition of Celularity’s UltraMIST® assets, SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate tissue regeneration biological signaling and angiogenic responses, producing new vascularization and microcirculatory improvement combined with tissue growth which helps restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac/endovascular conditions.For additional information about the Company, visit www. www sanuwave.com.Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.Contact:SANUWAVE Health, Inc. Kevin Richardson II Chairman and Chief Executive Officer 978-922-2447 investorrelations@sanuwave.comAnne Marie FieldsManaging DirectorRx Communications Groupafields@rxir.com1 Richmond NA, Maderal AD, Vivas AC. Evidence-based management of common chronic lower extremity ulcers. Dermatol Ther 2013;26:187–196 [PubMed] [Google Scholar]2  Canadian Agency for Drugs and Technologies in Health. Optimal Care of Chronic, Non-Healing, Lower Extremity Wounds: A Review of Clinical Evidence and Guidelines. Ottawa, ON, Canada, 2013 [Google Scholar]

  • GlobeNewswire

    SANUWAVE Health Hosts Symposium on dermaPACE at Wounds Canada Virtual Conference

    World Renowned Wound Care Experts to Lead Discussion on Role of dermaPACE in the Treatment of Chronic Wounds SUWANEE, GA, Sept. 22, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (OTCQB: SNWV), whose focus is the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin, musculoskeletal tissue and vascular structures, announced today that the Company is sponsoring a dermaPACE® educational symposium at the upcoming Wounds Canada Virtual Conference taking place October 14 – 18, 2020.  The educational symposium entitled, “Innovative Energy Transfer Medical System: PACE®-Focused Shockwave Technology Facilitates Revascularization and Capillary Perfusion in Chronic Wounds,” will take place on Saturday, October 17, 2020 at 8:00 am EDT.   The symposium will feature renowned leaders in the wound care sector:  David G. Armstrong, M.D., Keck School of Medicine at University of Southern California and Perry V. Mayer, M.D. Medical Director of the Mayer Institute in Hamilton, Ontario.  The event will be moderated by Robin Evans, M.D., Medical Director of the Wound Healing Clinic-Women’s College Hospital in Toronto and will include participation of Iulian Cioanta, Ph.D., Chief Science and Technology Officer of SANUWAVE Health.   “We are proud to support this educational symposium led by luminaries in the field before an audience of wound care specialists seeking to learn more about innovative treatments for their patients with chronic wounds,” stated Kevin A. Richardson II, Chairman and Chief Executive Officer of SANUWAVE Health. “The biologic responses activated by the dermaPACE® treatment continue to demonstrate improved revascularization and capillary perfusion needed to promote healing in these recalcitrant wounds.”“The dermaPACE® System has been particularly effective in speeding the healing process through improved microvascular perfusion in patients with diabetic, distal ischemia. We are also able to observe that the dermaPACE® System affects the healing of primarily closed wound sites with a dramatic reduction of edema, from between 3-4+ perioperatively to negligible amounts after the third shockwave treatment. The introduction of shockwave therapy to the patient’s treatment plan appears to hasten the overall healing affect (wound margin annealing) and allows the patients to return to normal weight-bearing activities sooner,” noted Dr. Mayer.To participate in the conference and symposium free of charge, please send a request and your contact information to WoundsCanada2020@Sanuwave.com.  About the dermaPACE® SystemThe dermaPACE® System is a novel device based on shockwave technology, which has been used for nearly 30 years in orthopedic treatments and lithotripsy procedures (destruction of kidney stones). These early devices also provided evidence that there was an effect on wound healing. Pulsed Acoustic Cellular Expression (PACE®) Technology was developed based on this evidence, and the dermaPACE® System is the first to utilize PACE-specific proprietary protocols for wound treatment.The dermaPACE® System is FDA cleared for the treatment of diabetic foot ulcers (DFU). ​​ The dermaPACE®   System is the first and only device based on shockwave principles cleared by the FDA for such indications.  For international markets, the dermaPACE® System is CE Marked in Europe for advanced wound care indications and in Canada the dermaPACE® System carries a Health Canada Medical Device class II License. The dermaPACE®   System and wound indications are currently licensed or approved in dozens of countries and regions around the world. About SANUWAVE Health, Inc.SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is focused on the development and commercialization of its patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.  Through its recent acquisition of Celularity’s UltraMIST assets, SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies with two human tissue biologic products to create a platform of scale with an end-to-end product offering in the advanced wound care market.  SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. For additional information about the Company, visit www. www sanuwave.com.Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.Contact:SANUWAVE Health, Inc. Kevin Richardson II Chairman and Chief Executive Officer 978-922-2447 investorrelations@sanuwave.comAnne Marie FieldsManaging DirectorRx Communications Group afields@rxir.com

  • GlobeNewswire

    CORRECTION - SANUWAVE Health Announces Reimbursement Coverage for BIOVANCE From Largest Medicare and Medicaid Administrator in U.S.

    24.5 Million Covered Lives Now Eligible for Biologic Advanced Wound Care Treatment Through Centene CorporationSUWANEE, GA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE \-- SANUWAVE Health, Inc. (OTCQB: SNWV), whose focus is the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin, musculoskeletal tissue and vascular structures, announced today that Centene Corporation, the largest Medicare and Medicaid Administrator in the U.S., has included BIOVANCE® in its list of reimbursed skin substitutes for advanced wound healing for the more than 24.5 million lives it covers. SANUWAVE, through its recent agreement with Cellularity, Inc., is the exclusive distributor for BIOVANCE in the U.S. wound care market. BIOVANCE is decellularized, dehydrated human amniotic membrane (DDHAM) that is an intact, natural extracellular matrix (ECM) that acts as a scaffold for restoration of functional tissue. BIOVANCE contains key ECM proteins that allow for the migration of host cells to permeate the graft and promote tissue repair when applied to a wound.  BIOVANCE brings the progenerative power of the amnion to tissue regeneration[i]1-6 and provides a foundation for the wound healing process. “Inclusion in Centene’s list of reimbursable skin substitutes for advanced wound healing products is a key milestone for BIOVANCE as we continue to expand our Medicare and Medicaid access to benefit the millions of elderly patients suffering with recalcitrant wounds,” said Ryan K. Sheffer, Senior Director Reimbursement & Health Policy for SANUWAVE Health.  “Moving forward, we expect to increase our coverage from national payors with a goal to gain access to the more than 250 million commercial and managed Medicare patients, which is expected to drive BIOVANCE revenue and grow SANUWAVE’s share in the multi-billion dollar advanced wound care market.” About Centene Corporation Centene Corporation, a Fortune 100 company, is a leading multi-national healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams - to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace, the TRICARE program, and individuals in correctional facilities. The Company also serves several international markets, and contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and the development of its people, systems and capabilities so that it can better serve its members, providers, local communities, and government partners.About SANUWAVE Health, Inc.SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is focused on the development and commercialization of its patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.  Through its recent acquisition of Celularity’s UltraMIST assets, SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies with two human tissue biologic products to create a platform of scale with an end-to-end product offering in the advanced wound care market.  SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. For additional information about the Company, visit www.sanuwave.com.Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.Contact:SANUWAVE Health, Inc. Kevin Richardson II Chairman and Chief Executive Officer 978-922-2447 investorrelations@sanuwave.comAnne Marie FieldsManaging DirectorRx Communications Group afields@rxir.com 1. Fetterolf DE, Synder RJ. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds. 2012;24(10):299-307. 2. Bhatia M, Pereira M, Rana H, et al. Mechanism of cell interaction and response on decellularized human amniotic membrane: implications in wound healing. Wounds. 2007;19(8):207-217. 3. Faulk WP, Matthews R, Stevens PJ, et al. Human amnion as an adjunct in wound healing. Lancet. 1980;1(8179):1156-1158. 4. Ganatra MA. Amniotic membrane in surgery. J Pak Med A. 2003;53(1):29-32. 5. Portmann-Lanz CB, Ochsenbein-Kölble N, Marquardt K, et al. Manufacture of a cell-free amnion matrix scaffold that supports amnion cell outgrowth in vitro. Placenta. 2007;28(1):6-13. 6. Niknejad H, Peirovl H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008;15:88-99.